Tokio Marine Asset Management Co. Ltd. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 26.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,589 shares of the medical research company’s stock after selling 2,750 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Amgen were worth $1,307,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. TrimTabs Asset Management LLC raised its position in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC raised its position in shares of Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after purchasing an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the last quarter. American Beacon Advisors Inc. purchased a new position in shares of Amgen in the 1st quarter worth about $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen in the 1st quarter worth about $121,000. Hedge funds and other institutional investors own 78.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Tokio Marine Asset Management Co. Ltd. Reduces Stake in Amgen Inc. (AMGN)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/09/tokio-marine-asset-management-co-ltd-reduces-stake-in-amgen-inc-amgn.html.

Amgen Inc. (NASDAQ:AMGN) opened at 185.82 on Monday. The firm has a 50-day moving average price of $181.33 and a 200-day moving average price of $170.23. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The stock has a market cap of $135.59 billion, a price-to-earnings ratio of 16.93 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $2.84 earnings per share. Equities research analysts expect that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Friday. Mizuho reaffirmed a “buy” rating and issued a $198.00 price target on shares of Amgen in a research report on Friday. Morgan Stanley reaffirmed an “overweight” rating and issued a $196.00 price target (up previously from $189.00) on shares of Amgen in a research report on Friday. Cann reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Friday. Finally, Bank of America Corporation lifted their price target on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday. Ten equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $189.99.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.